High levels of AAV vector integration into CRISPR-induced DNA breaks
- PMID: 31570731
- PMCID: PMC6769011
- DOI: 10.1038/s41467-019-12449-2
High levels of AAV vector integration into CRISPR-induced DNA breaks
Abstract
Adeno-associated virus (AAV) vectors have shown promising results in preclinical models, but the genomic consequences of transduction with AAV vectors encoding CRISPR-Cas nucleases is still being examined. In this study, we observe high levels of AAV integration (up to 47%) into Cas9-induced double-strand breaks (DSBs) in therapeutically relevant genes in cultured murine neurons, mouse brain, muscle and cochlea. Genome-wide AAV mapping in mouse brain shows no overall increase of AAV integration except at the CRISPR/Cas9 target site. To allow detailed characterization of integration events we engineer a miniature AAV encoding a 465 bp lambda bacteriophage DNA (AAV-λ465), enabling sequencing of the entire integrated vector genome. The integration profile of AAV-465λ in cultured cells display both full-length and fragmented AAV genomes at Cas9 on-target sites. Our data indicate that AAV integration should be recognized as a common outcome for applications that utilize AAV for genome editing.
Conflict of interest statement
The authors declare the following competing interests. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. B.P.K. and J.K.J. are inventors on various patents and patent applications that describe gene editing and epigenetic editing technologies. S.Q.T. is a co-inventor on patents and patent applications describing gene editing technologies and methods for defining their genome-wide activities. S.Q.T. is a member of the scientific advisory board of Kromatid Inc. J.S.C and N.E.B are co-inventors on muscle-specific gene editing patents; JSC has financial interests in Solid Biosciences. C.A.M. has a financial interest in Chameleon Biosciences, Inc., a company developing an enveloped adeno-associated virus (AAV) vector platform technology for repeated dosing of systemic gene therapy. M.J.A. holds equity in Excelsior Genomics. J.K.J, C.A.M., and M.J.A.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors declare no competing interests.
Figures
Similar articles
-
Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.AIDS Rev. 2017 Oct-Dec;19(3):167-172. AIDS Rev. 2017. PMID: 29019352
-
AAV Vectorization of DSB-mediated Gene Editing Technologies.Curr Gene Ther. 2016;16(3):207-19. doi: 10.2174/1566523216666160602213738. Curr Gene Ther. 2016. PMID: 27280971 Review.
-
AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.Thromb Res. 2024 Jun;238:151-160. doi: 10.1016/j.thromres.2024.04.031. Epub 2024 May 3. Thromb Res. 2024. PMID: 38718473
-
In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.Mol Ther. 2017 May 3;25(5):1168-1186. doi: 10.1016/j.ymthe.2017.03.012. Epub 2017 Mar 30. Mol Ther. 2017. PMID: 28366764 Free PMC article.
-
Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.Gene. 2024 Nov 15;927:148733. doi: 10.1016/j.gene.2024.148733. Epub 2024 Jun 28. Gene. 2024. PMID: 38945310 Review.
Cited by
-
Cell-Based Delivery Approaches for DNA-Binding Domains to the Central Nervous System.Curr Neuropharmacol. 2021;19(12):2125-2140. doi: 10.2174/1570159X19666210517144044. Curr Neuropharmacol. 2021. PMID: 33998992 Free PMC article. Review.
-
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1.EMBO Mol Med. 2024 Jan;16(1):112-131. doi: 10.1038/s44321-023-00008-8. Epub 2024 Jan 5. EMBO Mol Med. 2024. PMID: 38182795 Free PMC article.
-
CRISPR medicine for blood disorders: Progress and challenges in delivery.Front Genome Ed. 2023 Jan 6;4:1037290. doi: 10.3389/fgeed.2022.1037290. eCollection 2022. Front Genome Ed. 2023. PMID: 36687779 Free PMC article. Review.
-
AAV- based vector improvements unrelated to capsid protein modification.Front Med (Lausanne). 2023 Feb 3;10:1106085. doi: 10.3389/fmed.2023.1106085. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36817775 Free PMC article. Review.
-
Off-target effects in CRISPR/Cas9 gene editing.Front Bioeng Biotechnol. 2023 Mar 9;11:1143157. doi: 10.3389/fbioe.2023.1143157. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 36970624 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
